BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wienke J, Dierselhuis MP, Tytgat GAM, Künkele A, Nierkens S, Molenaar JJ. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. Eur J Cancer 2021;144:123-50. [PMID: 33341446 DOI: 10.1016/j.ejca.2020.11.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Yin X, Lin H, Lin L, Miao L, He J, Zhuo Z. LncRNAs and CircRNAs in cancer. MedComm 2022;3. [DOI: 10.1002/mco2.141] [Reference Citation Analysis]
2 Lu XY, Qu LJ, Duan XL, Zuo W, Sai K, Rui G, Gong XF, Ding YB, Gao Q. Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy. Front Pediatr 2022;10:898918. [PMID: 35757140 DOI: 10.3389/fped.2022.898918] [Reference Citation Analysis]
3 Holterhus M, Altvater B, Kailayangiri S, Rossig C. The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers (Basel) 2022;14:2177. [PMID: 35565307 DOI: 10.3390/cancers14092177] [Reference Citation Analysis]
4 Xia Y, Li X, Tian X, Zhao Q. Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma. Front Mol Biosci 2021;8:769661. [PMID: 34950701 DOI: 10.3389/fmolb.2021.769661] [Reference Citation Analysis]
5 Bussola N, Papa B, Melaiu O, Castellano A, Fruci D, Jurman G. Quantification of the Immune Content in Neuroblastoma: Deep Learning and Topological Data Analysis in Digital Pathology. Int J Mol Sci 2021;22:8804. [PMID: 34445517 DOI: 10.3390/ijms22168804] [Reference Citation Analysis]
6 Brignole C, Bensa V, Fonseca NA, Del Zotto G, Bruno S, Cruz AF, Malaguti F, Carlini B, Morandi F, Calarco E, Perri P, Moura V, Emionite L, Cilli M, De Leonardis F, Tondo A, Amoroso L, Conte M, Garaventa A, Sementa AR, Corrias MV, Ponzoni M, Moreira JN, Pastorino F. Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. J Exp Clin Cancer Res 2021;40:180. [PMID: 34078433 DOI: 10.1186/s13046-021-01993-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Quinn CH, Beierle AM, Beierle EA. Artificial Tumor Microenvironments in Neuroblastoma. Cancers (Basel) 2021;13:1629. [PMID: 33915765 DOI: 10.3390/cancers13071629] [Reference Citation Analysis]
8 Li W, Li X, Xia Y, Wang J. Pyroptosis-Related Gene Signature Predicts the Prognosis and Immune Infiltration in Neuroblastoma. Front Genet 2022;13:809587. [DOI: 10.3389/fgene.2022.809587] [Reference Citation Analysis]
9 Zhang L, Wang M, Zhu Z, Ding C, Chen S, Wu H, Yang Y, Che F, Li Q, Li H. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy. Int J Nanomedicine 2021;16:3217-40. [PMID: 34007175 DOI: 10.2147/IJN.S302450] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M, Mazzocco K. Molecular Genetics in Neuroblastoma Prognosis. Children (Basel) 2021;8:456. [PMID: 34072462 DOI: 10.3390/children8060456] [Reference Citation Analysis]
11 Gupta A, Cripe TP. Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatr Drugs 2021. [PMID: 34822115 DOI: 10.1007/s40272-021-00482-y] [Reference Citation Analysis]
12 Liu X, Wills CA, Chen L, Zhang J, Zhao Y, Zhou M, Sundstrom JM, Schell T, Spiegelman VS, Young MM, Wang HG. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. J Immunother Cancer 2022;10:e004399. [PMID: 35483745 DOI: 10.1136/jitc-2021-004399] [Reference Citation Analysis]
13 Shim J, Goldsmith KC. A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers (Basel) 2021;13:4650. [PMID: 34572875 DOI: 10.3390/cancers13184650] [Reference Citation Analysis]
14 Liu Z, Chen X, Roberts R, Huang R, Mikailov M, Tong W. Unraveling Gene Fusions for Drug Repositioning in High-Risk Neuroblastoma. Front Pharmacol 2021;12:608778. [PMID: 33967751 DOI: 10.3389/fphar.2021.608778] [Reference Citation Analysis]
15 Verhoeven BM, Mei S, Olsen TK, Gustafsson K, Valind A, Lindström A, Gisselsson D, Fard SS, Hagerling C, Kharchenko PV, Kogner P, Johnsen JI, Baryawno N. The immune cell atlas of human neuroblastoma. Cell Rep Med 2022;3:100657. [PMID: 35688160 DOI: 10.1016/j.xcrm.2022.100657] [Reference Citation Analysis]
16 Sha Y, Han L, Sun B, Zhao Q. Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma. Front Cell Dev Biol 2021;9:769580. [PMID: 35071226 DOI: 10.3389/fcell.2021.769580] [Reference Citation Analysis]
17 Strijker JGM, Pscheid R, Drent E, van der Hoek JJF, Koopmans B, Ober K, van Hooff SR, Kholosy WM, Cornel AM, Coomans C, Bisso A, van Loenen MM, Molenaar JJ, Wienke J. αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. J Pers Med 2021;11:923. [PMID: 34575700 DOI: 10.3390/jpm11090923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 El Moukhtari SH, Garbayo E, Fernández-Teijeiro A, Rodríguez-Nogales C, Couvreur P, Blanco-Prieto MJ. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system. J Control Release 2022;348:553-71. [PMID: 35705114 DOI: 10.1016/j.jconrel.2022.06.010] [Reference Citation Analysis]
19 Martínez-Sanz P, Hoogendijk AJ, Verkuijlen PJJH, Schornagel K, van Bruggen R, van den Berg TK, Tytgat GAM, Franke K, Kuijpers TW, Matlung HL. CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. Cancers (Basel) 2021;13:4261. [PMID: 34503071 DOI: 10.3390/cancers13174261] [Reference Citation Analysis]
20 Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T; Japan Children’s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Jpn J Clin Oncol 2022:hyac007. [PMID: 35137156 DOI: 10.1093/jjco/hyac007] [Reference Citation Analysis]
21 Ning L, Shim J, Tomov ML, Liu R, Mehta R, Mingee A, Hwang B, Jin L, Mantalaris A, Xu C, Mahmoudi M, Goldsmith KC, Serpooshan V. A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior. Adv Sci (Weinh) 2022;:e2200244. [PMID: 35644929 DOI: 10.1002/advs.202200244] [Reference Citation Analysis]
22 Luo B, Wang L, Gao W, Su Y, Lu Y, Zheng J, Yin J, Zhao Q, Li J, Da Y, Li L. Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients. Front Immunol 2022;13:845757. [DOI: 10.3389/fimmu.2022.845757] [Reference Citation Analysis]
23 Spasov NJ, Dombrowski F, Lode HN, Spasova M, Ivanova L, Mumdjiev I, Burnusuzov H, Siebert N. First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma. J Pediatr Hematol Oncol 2022. [PMID: 35622995 DOI: 10.1097/MPH.0000000000002488] [Reference Citation Analysis]
24 Kang W, Hu J, Zhao Q, Song F. Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma. Front Cell Dev Biol 2021;9:731380. [PMID: 34746127 DOI: 10.3389/fcell.2021.731380] [Reference Citation Analysis]
25 Sowińska M, Szeliga M, Morawiak M, Ziemińska E, Zabłocka B, Urbańczyk-Lipkowska Z. Peptide Dendrimers with Non-Symmetric Bola Structure Exert Long Term Effect on Glioblastoma and Neuroblastoma Cell Lines. Biomolecules 2021;11:435. [PMID: 33804286 DOI: 10.3390/biom11030435] [Reference Citation Analysis]